Transcriptome Analysis of Pancreatic Cancer Reveals a Tumor Suppressor Function for HNF1A
Overview
Authors
Affiliations
Pancreatic ductal adenocarcinoma (PDAC) is driven by the accumulation of somatic mutations, epigenetic modifications and changes in the micro-environment. New approaches to investigating disruptions of gene expression networks promise to uncover key regulators and pathways in carcinogenesis. We performed messenger RNA-sequencing in pancreatic normal (n = 10) and tumor (n = 8) derived tissue samples, as well as in pancreatic cancer cell lines (n = 9), to determine differential gene expression (DE) patterns. Sub-network enrichment analyses identified HNF1A as the regulator of the most significantly and consistently dysregulated expression sub-network in pancreatic tumor tissues and cells (median P = 7.56×10(-7), median rank = 1, range = 1-25). To explore the effects of HNF1A expression in pancreatic tumor-derived cells, we generated stable HNF1A-inducible clones in two pancreatic cancer cell lines (PANC-1 and MIA PaCa-2) and observed growth inhibition (5.3-fold, P = 4.5×10(-5) for MIA PaCa-2 clones; 7.2-fold, P = 2.2×10(-5) for PANC-1 clones), and a G0/G1 cell cycle arrest and apoptosis upon induction. These effects correlated with HNF1A-induced down-regulation of 51 of 84 cell cycle genes (e.g. E2F1, CDK2, CDK4, MCM2/3/4/5, SKP2 and CCND1), decreased expression of anti-apoptotic genes (e.g. BIRC2/5/6 and AKT) and increased expression of pro-apoptotic genes (e.g. CASP4/9/10 and APAF1). In light of the established role of HNF1A in the regulation of pancreatic development and homeostasis, our data suggest that it also functions as an important tumor suppressor in the pancreas.
Allelic effects on expression likely mediated by JunB/D underlie a PDAC GWAS signal at chr1p36.33.
Connelly K, Hullin K, Abdolalizadeh E, Zhong J, Eiser D, OBrien A medRxiv. 2024; .
PMID: 39371158 PMC: 11451706. DOI: 10.1101/2024.09.16.24313748.
Knockouts of , , or from cholesterol synthesis reveal pathways modulated by sterol intermediates.
Skubic C, Trcek H, Nassib P, Kreft T, Walakira A, Pohar K iScience. 2024; 27(9):110651.
PMID: 39262789 PMC: 11387598. DOI: 10.1016/j.isci.2024.110651.
Genetic and other risk factors for pancreatic ductal adenocarcinoma (PDAC).
Jacobs M, Stoffel E Fam Cancer. 2024; 23(3):221-232.
PMID: 38573398 DOI: 10.1007/s10689-024-00372-5.
HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1.
Xia R, Hu C, Ye Y, Zhang X, Li T, He R Int J Oncol. 2023; 62(4).
PMID: 36825600 PMC: 9990585. DOI: 10.3892/ijo.2023.5493.
HNF1A Mutations and Beta Cell Dysfunction in Diabetes.
Miyachi Y, Miyazawa T, Ogawa Y Int J Mol Sci. 2022; 23(6).
PMID: 35328643 PMC: 8948720. DOI: 10.3390/ijms23063222.